It is important to note that the antiemetic drug Aprepitant is the NK-1R antagonist exerting an anticancer action (apoptosis) against as many as 21 different tumor types (Table 1); this is pivotal for its repurposing as an anticancer drug. Here, TACR1 is linked to neoplasm.